7sakurbayashi T,Takaesu Y,Haginoshita S,et al.lmprovement of my oeardial fatty acid metabolism through L-carnitine administration to ehronie hemodialysis patients[J].Am J phrol,1999,19(6):480-484.
6Kamyar Kalantar- Zadeh, Gladys Block, Michael H. Humphreys, et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int, 2003, 63 (3): 793-808
7Avram MM, Bonomini LV, Sreedhara R, et al. Predictive value of nu tritional markers (albumin, creatinine, cholesterol, and hematocrit) for patients on dialysis for up to 30 years. Am J Kidney Dis, 1996, 28:910 -917
8Madhumathi Rao, Brian J.G. Pereira: Prospective trials on anemia of chronic disease: The trial to reduce cardiovascular events with Aranesp therapy. Kidney Int, 2003, 64 (Suppl 87): S12 - S19
9Kletzmayr J, Mayer G, Legenstein E, et al. Anemia and carnitine supplementation in hemodialyzed patients[J]. Kindeny Int, 1999,55(Suppl69):S93 - S106.
10Caruso U, Leone L, Cravotto E, et al. Effects of L-carnitine on anemia in aged hemodialysis patiens treated with recombinant human erythropoietin: a pilot study [ J ]. Dialysis Transplant, 1998, 27 (4): 498 - 506.
